BR112022006946A2 - Cassete de transferência de aav - Google Patents
Cassete de transferência de aavInfo
- Publication number
- BR112022006946A2 BR112022006946A2 BR112022006946A BR112022006946A BR112022006946A2 BR 112022006946 A2 BR112022006946 A2 BR 112022006946A2 BR 112022006946 A BR112022006946 A BR 112022006946A BR 112022006946 A BR112022006946 A BR 112022006946A BR 112022006946 A2 BR112022006946 A2 BR 112022006946A2
- Authority
- BR
- Brazil
- Prior art keywords
- aav transfer
- transfer cassette
- cassettes
- aav
- plasmids
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CASSETE DE TRANSFERÊNCIA DE AAV. A presente invenção refere-se a cassetes e plasmídeos de transferência de AAV utilizados na produção de vetores virais adenoassociados recombinantes (rAAV). Os cassetes e plasmídeos descritos compreendem um ou mais transgenes tendo eficácia terapêutica na melhora, tratamento e/ou prevenção de uma ou mais doenças ou distúrbios, tal como Doença de Niemann-Pick, tipo C1 (NPC1).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962916749P | 2019-10-17 | 2019-10-17 | |
US201962923253P | 2019-10-18 | 2019-10-18 | |
PCT/US2020/056015 WO2021076911A1 (en) | 2019-10-17 | 2020-10-16 | Aav transfer cassette |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022006946A2 true BR112022006946A2 (pt) | 2022-08-23 |
Family
ID=73344131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022006946A BR112022006946A2 (pt) | 2019-10-17 | 2020-10-16 | Cassete de transferência de aav |
Country Status (14)
Country | Link |
---|---|
US (2) | US20240131185A1 (pt) |
EP (1) | EP4045524A1 (pt) |
JP (1) | JP2022551744A (pt) |
KR (1) | KR20220083708A (pt) |
CN (1) | CN114585743A (pt) |
AU (1) | AU2020367825A1 (pt) |
BR (1) | BR112022006946A2 (pt) |
CA (1) | CA3157702A1 (pt) |
CL (1) | CL2022000938A1 (pt) |
CO (1) | CO2022004652A2 (pt) |
IL (1) | IL292264A (pt) |
MX (1) | MX2022004353A (pt) |
TW (1) | TW202128737A (pt) |
WO (1) | WO2021076911A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ,インコーポレイテッド | ニーマン・ピック病c型の治療のためのアデノ随伴ウイルスベクター |
WO2023221942A1 (en) * | 2022-05-16 | 2023-11-23 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant aav vectors for treating glutaric aciduria type i |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2982129A1 (en) * | 2015-04-08 | 2016-10-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral gene therapy as treatment for cholesterol storage disease or disorder |
CA3019315A1 (en) * | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
JP7066619B2 (ja) * | 2015-12-11 | 2022-05-13 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス(aav)を誘導するための標的指向性ペプチド |
CA3071769A1 (en) * | 2017-07-31 | 2019-02-07 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
-
2020
- 2020-10-15 US US17/769,615 patent/US20240131185A1/en active Pending
- 2020-10-16 EP EP20804714.2A patent/EP4045524A1/en active Pending
- 2020-10-16 CA CA3157702A patent/CA3157702A1/en active Pending
- 2020-10-16 TW TW109136019A patent/TW202128737A/zh unknown
- 2020-10-16 AU AU2020367825A patent/AU2020367825A1/en active Pending
- 2020-10-16 US US17/072,637 patent/US20210128652A1/en active Pending
- 2020-10-16 KR KR1020227012835A patent/KR20220083708A/ko unknown
- 2020-10-16 BR BR112022006946A patent/BR112022006946A2/pt unknown
- 2020-10-16 JP JP2022522332A patent/JP2022551744A/ja active Pending
- 2020-10-16 MX MX2022004353A patent/MX2022004353A/es unknown
- 2020-10-16 CN CN202080073371.6A patent/CN114585743A/zh active Pending
- 2020-10-16 WO PCT/US2020/056015 patent/WO2021076911A1/en active Application Filing
-
2022
- 2022-04-12 CO CONC2022/0004652A patent/CO2022004652A2/es unknown
- 2022-04-13 CL CL2022000938A patent/CL2022000938A1/es unknown
- 2022-04-13 IL IL292264A patent/IL292264A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220083708A (ko) | 2022-06-20 |
CL2022000938A1 (es) | 2023-01-20 |
JP2022551744A (ja) | 2022-12-13 |
IL292264A (en) | 2022-06-01 |
CO2022004652A2 (es) | 2022-04-29 |
EP4045524A1 (en) | 2022-08-24 |
US20240131185A1 (en) | 2024-04-25 |
MX2022004353A (es) | 2022-07-19 |
CN114585743A (zh) | 2022-06-03 |
US20210128652A1 (en) | 2021-05-06 |
WO2021076911A1 (en) | 2021-04-22 |
AU2020367825A1 (en) | 2022-05-12 |
CA3157702A1 (en) | 2021-04-22 |
TW202128737A (zh) | 2021-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022006946A2 (pt) | Cassete de transferência de aav | |
PE20211419A1 (es) | Vectores virales recombinantes y acidos nucleicos para producirlos | |
CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
PE20190129A1 (es) | Capsides variantes de virus adenoasociados y metodos de uso de estas | |
WO2019060454A3 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
BR112016025263A2 (pt) | vetores de avv para terapia genética retiniana e do snc | |
JP2018537984A5 (pt) | ||
IL202522A (en) | Use of a recombinant adenovirus (aav) aav4 or aav5 containing a transgene encoding sphingomyelinase to produce an intraventricular drug for distribution in the epidermal cell layer of the ventricular system to treat Neiman-Peak type A disease or disease | |
JP2014040433A5 (pt) | ||
BR112022006530A2 (pt) | Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c | |
RU2011149094A (ru) | Генная терапия нейродегенеративных нарушений | |
JPWO2019156137A5 (pt) | ||
WO2020242984A9 (en) | Modified viral particles and uses thereof | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
MX2020006764A (es) | Una proteína de la cápside de raav modificada para terapia génica. | |
BR112018075692A2 (pt) | genes cln1 otimizados e cassetes de expressão e seu uso | |
BR112022015979A2 (pt) | Vetores de terapia genética para tratamento de doenças cardíacas | |
EP4055174A4 (en) | TRANSGENIC CASSETTES, AAV VECTORS AND AAV VIRAL VECTORS FOR EXPRESSION OF THE SLC6A1 GENE WITH OPTIMIZED HUMAN CODONS | |
CO2021008877A2 (es) | Uso de vectores lentivirales que expresan el factor ix | |
AR120252A1 (es) | Casete de transferencia de aav | |
CO2022006772A2 (es) | Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno | |
BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
AR122285A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad de sanfilippo y otros trastornos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SAREPTA THERAPEUTICS, INC. (US) |